Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression

References

• Poturnajova M, Furielova T, Balintova S, Schmidtova S, Kucerova L, Matuskova M. Molecular features and gene expression signature of metastatic colorectal cancer. Oncol Rep. 2021;45(4). doi:10.3892/or.2021.7961
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386(6625):623–627. doi:10.1038/386623a0
   PubMed Web of Science ®Google Scholar
• Lynch HT, Cristofaro G, Rozen P, et al. History of the international collaborative group on hereditary non polyposis colorectal cancer. Fam Cancer. 2003;2(Suppl 1):3–5. doi:10.1023/a:1025001714023
   PubMedGoogle Scholar
• Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342(2):69–77. doi:10.1056/NEJM200001133420201
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681–8686. doi:10.1073/pnas.96.15.8681
   PubMed Web of Science ®Google Scholar
• Bosman F, Yan P. Molecular pathology of colorectal cancer. Pol J Pathol. 2014;65(4):257–266. doi:10.5114/pjp.2014.48094
   PubMed Web of Science ®Google Scholar
• Di J, Liu M, Fan Y, et al. Phenotype molding of T cells in colorectal cancer by single-cell analysis. Int J Cancer. 2020;146(8):2281–2295. doi:10.1002/ijc.32856
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. doi:10.1146/annurev.immunol.23.021704.115611
   PubMed Web of Science ®Google Scholar
• Rau TT, Atreya R, Aust D, et al. Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation. J Pathol Clin Res. 2016;2(2):113–124. doi:10.1002/cjp2.41
   PubMedGoogle Scholar
• Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115–123. doi:10.1016/j.humpath.2018.08.020
   PubMed Web of Science ®Google Scholar
• Green AR, Aleskandarany MA, Ali R, et al. Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers. Cancer Immunol Res. 2017;5(4):292–299. doi:10.1158/2326-6066.CIR-16-0195
   PubMed Web of Science ®Google Scholar
• Menoni H, Wienholz F, Theil AF, et al. The transcription-coupled DNA repair-initiating protein CSB promotes XRCC1 recruitment to oxidative DNA damage. Nucleic Acids Res. 2018;46(15):7747–7756. doi:10.1093/nar/gky579
   PubMed Web of Science ®Google Scholar
• Moller K, Blessin NC, Hoflmayer D, et al. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Acta Oncol. 2021;60(9):1210–1217. doi:10.1080/0284186X.2021.1933585
   PubMed Web of Science ®Google Scholar
• Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of p53 dysfunction in colorectal cancer and its implication for therapy. Cancers. 2021;13(10):2296. doi:10.3390/cancers13102296
   PubMed Web of Science ®Google Scholar
• Bui VM, Mettling C, Jou J, Sun HS. Genomic amplification of chromosome 20q13.33 is the early biomarker for the development of sporadic colorectal carcinoma. BMC Med Genomics. 2020;13(Suppl 10):149. doi:10.1186/s12920-020-00776-z
   PubMedGoogle Scholar
• Kim HC, Roh SA, Ga IH, Kim JS, Yu CS, Kim JC. CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J Gastroenterol Hepatol. 2005;20(12):1920–1926. doi:10.1111/j.1440-1746.2005.03943.x
   PubMed Web of Science ®Google Scholar
• Ho V, Ashbury JE, Taylor S, Vanner S, King WD. Genetic and epigenetic variation in the DNMT3B and MTHFR genes and colorectal adenoma risk. Environ Mol Mutagen. 2016;57(4):261–268. doi:10.1002/em.22010
   PubMed Web of Science ®Google Scholar
• Andersen V, Vogel LK, Kopp TI, et al. High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence. PLoS One. 2015;10(3):e0119255. doi:10.1371/journal.pone.0119255
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang W. Effects of XRCC1 Arg399Gln gene polymorphism on platinum-based chemotherapy sensitivity and clinical prognosis in patients with colorectal cancer: a meta-analysis. Zhejiang Med. 2020;14. doi:10.12056/j.issn.1006-2785.2020.42.14.2019-3737
   Google Scholar
• Whitehouse CJ, Taylor RM, Thistlethwaite A, et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104(1):107–117. doi:10.1016/s0092-8674(01)00195-7
   PubMed Web of Science ®Google Scholar
• Gong L, Luo M, Sun R, Qiu L, Chen C, Luo Z. Significant association between XRCC1 expression and its rs25487 polymorphism and radiotherapy-related cancer prognosis. Front Oncol. 2021;11:654784. doi:10.3389/fonc.2021.654784
   PubMed Web of Science ®Google Scholar
• IJspeert JE, Vermeulen L, Meijer GA, Dekker E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol. 2015;12(7):401–409. doi:10.1038/nrgastro.2015.73
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E. Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate. Clin Cancer Res. 2020;26(1):11–17. doi:10.1158/1078-0432.CCR-18-0856
   PubMed Web of Science ®Google Scholar
• Sultana R, Abdel-Fatah T, Abbotts R, et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013;73(5):1621–1634. doi:10.1158/0008-5472.CAN-12-2929
   PubMed Web of Science ®Google Scholar
• Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(6):1595–1605. doi:10.1038/bjc.2014.46
   PubMed Web of Science ®Google Scholar
• Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–366. doi:10.1002/path.2774
   PubMed Web of Science ®Google Scholar
• Rubio CA, Jacobsson B, Castanos-Velez E. Cytotoxic intraepithelial lymphocytes in colorectal polyps and carcinomas. Anticancer Res. 1999;19(4B):3221–3227.
   PubMed Web of Science ®Google Scholar